Feature | May 12, 2014

Remote Patient Management Study Demonstrates Significant Reduction in Mortality and Hospitalization

PREDICt-RM collaborative study highlights improved outcomes in ICD and CRT-D patients followed with Latitude system


May 12, 2014 — Patients using the Boston Scientific Latitude remote patient management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with Latitude-compatible devices who were not followed on the system, according to results from the PREDICt-RM study (Patient RElated Determinants of ICD Remote Monitoring Utilization and Outcomes). The results were presented at Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

PREDICt-RM demonstrated a 33 percent relative reduction in the risk of death in patients with Boston Scientific ICDs (implantable cardioverter-defibrillators) and CRT-Ds (cardiac resynchronization therapy devices) who were remotely monitored via Latitude, compared to patients who were not remotely monitored. Additionally, these patients experienced a 19 percent relative reduction in hospitalizations for any cause. The study outcomes were presented by Joseph Akar, M.D., Ph.D., associate professor of medicine at Yale University and the Center for Outcomes Research and Evaluation (CORE) in New Haven, Conn., and are a result of collaboration between Yale CORE, the American College of Cardiology (ACC) and Boston Scientific.

"The PREDICt-RM results demonstrate improved outcomes for those ICD and CRT-D patients using the Latitude wireless remote patient management system," said Akar. "Despite the widespread availability of this technology, we know that it is underutilized. Our hope is that this study may inform clinical practice guidelines and promote the routine use of this technology in daily practice."

PREDICt-RM’s results were made possible via a unique research design that linked three large healthcare databases, illuminating the potential for "big data" and healthcare analytics to advance patient care. PREDICt-RM combined the National Cardiovascular Data Registry (NCDR) from ACC, CMS data from Medicare, and the Boston Scientific Latitude system. 

"No single database could have answered this question effectively. Through an innovative collaboration with ACC and Boston Scientific, we were able to leverage the strengths of each database to develop a deeper understanding of the association of remote monitoring with patient outcomes. We believe the PREDICt-RM experience should serve as a model for this type of investigation," said Jeptha Curtis, M.D., associate professor of medicine at Yale University and CORE.

"PREDICt-RM demonstrates that wireless remote monitoring using the Latitude system provides a significant benefit to patients and the overall healthcare system," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are very excited to have such strong data demonstrating substantially improved survival and reduced hospitalization rates in the patients followed on Latitude."

The Latitude remote patient management system connects a home communicator to the patient's implanted Boston Scientific device through wireless telemetry, enabling automatic collection of patient data. The system capabilities include transmitting physiologic data, as well as data gathered from the implanted device to the healthcare team's Latitude website. The Latitude system is the only implanted-device monitoring system with integrated physiologic monitoring of weight and blood pressure in the United States.

For more information: www.bostonscientific.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now